Anti-Coagulants - Brunei Darussalam

Brunei Darussalam

In Brunei Darussalam, the revenue in the Anti-Coagulants market is estimated to reach US$1.05m in 2024.
It is anticipated that the revenue will experience an annual growth rate (CAGR 2024-2028) of 7.26%, leading to a market volume of US$1.39m by 2028.
When compared globally, United States is projected to generate the highest revenue of US$16,740.00m in 2024.
Brunei Darussalam's growing aging population is driving an increasing demand for anti-coagulants as a preventative measure against cardiovascular diseases.

Key regions: Germany, South Korea, France, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Brunei Darussalam has been experiencing steady growth in recent years.

Customer preferences: Patients in Brunei Darussalam are increasingly opting for Anti-Coagulants as a treatment for blood clots and related conditions. This can be attributed to the rising awareness about the benefits of Anti-Coagulants in preventing strokes and other cardiovascular diseases.

Trends in the market: The Anti-Coagulants market in Brunei Darussalam is witnessing a trend towards the use of newer oral Anti-Coagulants over traditional injectable ones. This is because oral Anti-Coagulants offer greater convenience and ease of use for patients. Additionally, there is a growing preference for Anti-Coagulants that have a lower risk of causing bleeding complications.

Local special circumstances: Brunei Darussalam has a small population with a high prevalence of chronic diseases such as diabetes and hypertension. This has led to a growing demand for Anti-Coagulants as a preventive measure against blood clots and related complications.

Underlying macroeconomic factors: The healthcare sector in Brunei Darussalam is growing, with the government investing in the development of healthcare infrastructure and services. This has led to an increase in the availability of Anti-Coagulants and other medical treatments in the country. Additionally, Brunei Darussalam has a high per capita income, which allows patients to afford the relatively high cost of Anti-Coagulants.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.